The estimated Net Worth of Avermaete David Van is at least $64.5 Tausend dollars as of 30 April 2024. Mr. Van owns over 5,396 units of Neurometrix stock worth over $30,327 and over the last 11 years he sold NURO stock worth over $0. In addition, he makes $34,130 as Independent Director at Neurometrix.
David has made over 2 trades of the Neurometrix stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 5,396 units of NURO stock worth $23,581 on 30 April 2024.
The largest trade he's ever made was exercising 17,647 units of Neurometrix stock on 2 May 2023 worth over $24,529. On average, David trades about 1,097 units every 17 days since 2013. As of 30 April 2024 he still owns at least 7,601 units of Neurometrix stock.
You can see the complete history of Mr. Van stock trades at the bottom of the page.
David Van Avermaete serves as Independent Director of the Company. Mr. Van Avermaete has served as President of Inject Safe Technologies, a privately held company that has developed a bandage specifically designed to support injections. From April 2004 to February 2013, Mr. Van Avermaete served as Chief Executive Officer of VeraLight, Inc., a medical device company he founded, that focuses on non-invasive screening for type 2 diabetes. From 2000 to 2004, Mr. Van Avermaete served as Senior Vice President Non-Invasive Technology of InLight Solutions, a Johnson & Johnson company focused on transformational technology in the diabetes field. From 1998 to 2000, Mr. Van Avermaete served as U.S. President of the LifeScan division of Johnson & Johnson and, from 1990 to 1998, in various senior level positions at LifeScan concentrating in sales and marketing. Previously, Mr. Van Avermaete served as Vice President Sales and Marketing at Biotope, Director of Marketing at Roche Diagnostics, and Director of Marketing and Sales at Syntex Medical Diagnostics. Mr. Van Avermaete received a Master of Business Administration and a Master of Science Degree in Microbiology from the University of Arizona and a Bachelor of Science Degree in medical technology and chemistry from Ball State University. The Board has concluded that Mr. Van Avermaete should serve as a director because his executive level experience in the medical device and diabetes field, as well as in entrepreneurial ventures, provides the Board with a valuable perspective in commercializing medical device products.
As the Independent Director of Neurometrix, the total compensation of David Avermaete at Neurometrix is $34,130. There are 7 executives at Neurometrix getting paid more, with Shai Gozani having the highest compensation of $775,030.
David Avermaete is 68, he's been the Independent Director of Neurometrix since 2013. There are 1 older and 5 younger executives at Neurometrix. The oldest executive at Neurometrix Inc. is Thomas T. Higgins, 69, who is the Sr. VP, CFO & Treasurer.
Avermaete's mailing address filed with the SEC is C/O NEUROMETRIX, INC., 4B GILL STREET, WOBURN, MA, 01801.
Over the last 20 years, insiders at Neurometrix have traded over $14,886,276 worth of Neurometrix stock and bought 3,074,896 units worth $6,396,868 . The most active insiders traders include James Edeerfield Capital Lp..., Capital Partners, Lp Topline und Capital Management, Llc Mc .... On average, Neurometrix executives and independent directors trade stock every 45 days with the average trade being worth of $133,905. The most recent stock trade was executed by Thomas T Higgins on 2 May 2024, trading 498 units of NURO stock currently worth $2,226.
neurometrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. the company maintains an active research effort and has several pipeline programs. the company is located in waltham, massachusetts and was founded as a spinoff from the harvard-mit division of health sciences and technology in 1996. for more information, please visit neurometrix.com. neurometrix markets the following products: quell® wearable pain relief technology™ quell is 100% drug free wearable technology that has changed the lives of people suffering with chronic pain. it combines clinical strength neurostimulation to treat pain with an easy-to-use app that helps people manage pain and reclaim their lives. quell is doctor recommended and designed for people with chronic back pain, arthritic pain, nerve pain, leg and foot pain, among other chronic pain conditions. quell launc
Neurometrix executives and other stock owners filed with the SEC include: